Organon & Co. (NYSE:OGN) Shares Acquired by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC grew its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 34.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,029,923 shares of the company's stock after purchasing an additional 521,847 shares during the period. Brandywine Global Investment Management LLC owned about 0.79% of Organon & Co. worth $30,286,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of OGN. Horizon Bancorp Inc. IN raised its holdings in shares of Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after purchasing an additional 1,585 shares during the period. Millstone Evans Group LLC purchased a new position in shares of Organon & Co. during the 4th quarter valued at about $29,000. Larson Financial Group LLC increased its holdings in shares of Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after buying an additional 1,734 shares during the period. Riverview Trust Co increased its stake in shares of Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after buying an additional 1,292 shares during the period. Finally, Versant Capital Management Inc lifted its holdings in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock worth $41,000 after buying an additional 1,324 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Organon & Co. Stock Down 7.5 %

Shares of OGN stock traded down $1.08 during trading hours on Friday, reaching $13.37. 1,579,977 shares of the company's stock were exchanged, compared to its average volume of 2,556,619. The company has a market cap of $3.45 billion, a price-to-earnings ratio of 4.01, a P/E/G ratio of 0.90 and a beta of 0.76. Organon & Co. has a fifty-two week low of $13.06 and a fifty-two week high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The stock's 50 day moving average is $15.22 and its 200-day moving average is $16.10.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 8.38%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s payout ratio is currently 33.63%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on OGN shares. Barclays reduced their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Morgan Stanley dropped their price target on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday, February 14th. Finally, TD Cowen raised shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.